IP Library Granted Patent US 11,332,757
Granted Patent B2
US 11,332,757 · App. 17/092,161 · Granted May 17, 2022

Delivery across cell plasma membranes

Inventors: Michael Maguire (Dublin, IE); Shirley O'Dea (Maynooth, IE)
Assignee: Avectas Limited
C12N15/895A61K31/7115B05B1/02B05B7/2491C12M35/04C12N5/00C12N5/0018C12N5/0636C12N5/0656C12N5/0662C12N15/113C12N15/87C12N2310/14C12N2500/12C12N2500/30C12N2500/34C12N2500/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,332,757
App. No.
17/092,161
Granted
May 17, 2022
Kind
B2
Abstract

Delivering a payload across a plasma membrane of a cell includes providing a population of cells and contacting the population of cells with a volume of an aqueous solution. The aqueous solution includes the payload and alcohol content greater than 5 percent concentration. The volume of the aqueous solution may be a function of exposed surface area of the population of cells, or may be a function of a number of cells in the population of cells. Related compositions, apparatus, systems, techniques, and articles are also described.

Claims (47)

1. A method for delivering a payload across a plasma membrane of a cell, comprising:

providing a population of cells; and

contacting the population of cells with a volume of aqueous solution, whereby the payload is subsequently delivered across the plasma membrane of the cell, the aqueous solution including the payload and an alcohol at a concentration greater than 2 percent (v/v); wherein the population of cells is in contact with the aqueous solution for 2 seconds to 2 minutes prior to adding a second volume of buffer or culture medium to submerse or suspend the population of cells,

wherein the population of cells comprises non-adherent cells, and the non-adherent cells include at least one of primary or immortalized hematopoietic stem cell (HSC), T cells, natural killer (NK) cells, cytokine-induced killer (CIK) cells, human cord blood CD34+ cells, B cells, or induced pluripotent stem cells;

wherein contacting the population of cells with the volume of aqueous solution is performed by gas propelling the aqueous solution to form a spray.

2. The method of claim 1 , wherein the volume of aqueous solution including the payload is between 6.0×10 −7 microliter per cell and 7.4×10 −4 microliter per cell.

3. The method of claim 1 , further comprising creating a cell occupied area by at least removing media from the population of cells such that the non-adherent cells rest on the cell occupied area, wherein a total volume of aqueous solution is delivered to the cell-occupied area, wherein (a) the total volume of aqueous solution is 20 μl and the cell-occupied area is about 1.9 cm 2 , wherein about is within 10 percent; or (b) the total volume of aqueous solution is 10 μl and the cell-occupied area is about 0.95 cm 2 , wherein about is within 10 percent.

4. The method of claim 1 , wherein said aqueous solution comprises an ethanol concentration of 5 to 30% (v/v).

5. The method of claim 1 , wherein said aqueous solution comprises one or more of 75 to 98% H 2 O, 2 to 45% ethanol, 6 to 91 mM sucrose, 2 to 35 mM potassium chloride, 2 to 35 mM ammonium acetate, and 1 to 14 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES).

6. The method of claim 1 , wherein the payload comprises a small chemical molecule, a peptide or protein, or a nucleic acid.

7. The method of claim 6 , wherein

(a) the small chemical molecule comprises a molecular mass of less than 1,000 Da;

(b) wherein the small chemical molecule comprises MitoTracker® Red CMXRos, propidium iodide, methotrexate, or DAPI (4′,6-diamidino-2-phenylindole);

(c) the peptide comprises ecallantide, liraglutide, or icatibant;

(d) the nucleic acid comprises a small-interfering RNA (siRNA), and wherein the siRNA molecule comprises a molecular mass of about 15,000 Da;

(e) the protein comprises a molecular mass about 1,000-150,000 Da;

(f) the protein comprises an antibody, or fragment thereof, and wherein the antibody or fragment thereof comprises an anti-actin antibody, an anti-GAPDH antibody, an anti-Src antibody, an anti-Myc ab, and an anti-Raf antibody; or

(g) the nucleic acid molecule comprises greater than 5,000,000 Da.

8. The method of claim 1 , wherein the payload comprises a therapeutic agent, a diagnostic agent, a fluorescent molecule, or a detectable nanoparticle.

9. The method of claim 8 , wherein (a) the therapeutic agent includes at least one of cisplatin, aspirin, a statin, and fluoxetine; (b) the diagnostic agent includes at least one of methylene blue, patent blue V, and indocyanine green; or (c) the nanoparticle comprises a quantum dot.

10. The method of claim 1 , further comprising creating a cell occupied area by at least removing media from the population of cells such that the non-adherent cells rest on the cell occupied area, wherein the population of cells at rest on the cell occupied area is substantially confluent, wherein substantially is greater than 75 percent confluent.

11. The method of claim 1 , further comprising creating a cell occupied area by at least removing media from the population of cells such that the non-adherent cells rest on the cell occupied area, wherein the population of cells at rest on the cell occupied area form a monolayer of cells.

12. The method of claim 1 , wherein the population of cells comprises macrophages.

13. The method of claim 1 , wherein the population of cells comprises mesenchymal stem cells.

14. The method of claim 1 , wherein the payload comprises nucleic acid.

15. The method of claim 1 , wherein the payload comprises mRNA.

16. The method of claim 1 , wherein the aqueous solution includes the alcohol at a concentration greater than 5 percent (v/v).

17. The method of claim 1 , wherein said aqueous solution comprises an ethanol at a concentration of 2 to 30% (v/v).

18. The method of claim 1 , wherein the volume of aqueous solution is delivered to the population of cells in the form of the spray.

19. The method of claim 18 , wherein the spray comprises a colloidal suspension comprising a diameter of 1 nm to 100 μm.

20. The method of claim 1 , wherein the buffer or culture medium comprises a second aqueous solution.

21. The method of claim 20 , wherein the second aqueous solution comprises saline.

22. The method of claim 21 , wherein the saline comprises phosphate buffered saline (PBS).

23. A method for delivering a payload across a plasma membrane of a cell, comprising:

providing a population of cells; and

contacting the population of cells with a volume of aqueous solution, whereby the payload is subsequently delivered across the plasma membrane of the cell, the aqueous solution including the payload and an alcohol at a concentration greater than 2 percent (v/v), wherein the population of cells is in contact with the aqueous solution for 2 seconds to 2 minutes prior to adding a second volume of buffer or culture medium to submerse or suspend the population of cells,

wherein the population of cells comprises adherent cells, and the adherent cells include at least one of primary or immortalized mesenchymal stem cells, lung cells, neuronal cells, fibroblasts, human umbilical vein (HUVEC) cells, and human embryonic kidney (HEK) cells,

wherein contacting the population of cells with the volume of aqueous solution is performed by gas propelling the aqueous solution to form a spray.

24. The method of claim 23 , wherein said aqueous solution comprises an ethanol concentration of 5 to 30% (v/v).

25. A method for delivering a payload across a plasma membrane of a cell, comprising:

providing a population of cells; and

contacting the population of cells with a volume of aqueous solution, whereby the payload is subsequently delivered across the plasma membrane of the cell, the aqueous solution including the payload and an alcohol at a concentration greater than 2 percent (v/v), wherein the population of cells is in contact with the aqueous solution for 2 seconds to 2 minutes prior to adding a second volume of buffer or culture medium to submerse or suspend the population of cells,

wherein contacting the population of cells with the volume of aqueous solution is performed by gas propelling the aqueous solution to form a spray,

and wherein the buffer or culture medium comprises a second aqueous solution.

26. The method of claim 25 , wherein the population of cells comprises adherent cells, and the adherent cells include at least one of primary or immortalized mesenchymal stem cells, lung cells, neuronal cells, fibroblasts, human umbilical vein (HUVEC) cells, or human embryonic kidney (HEK) cells.

27. The method of claim 25 , wherein the population of cells comprises non-adherent cells, and the non-adherent cells include at least one of primary or immortalized hematopoietic stem cell (HSC), T cells, natural killer (NK) cells, cytokine-induced killer (CIK) cells, human cord blood CD34+ cells, or B cells.

28. The method of claim 25 , wherein said aqueous solution comprises an ethanol concentration of 5 to 30% (v/v).

Assignments (2)
CHANGE OF NAME Recorded Mar 23, 2022
From: PROFECTOR LIFE SCIENCES LIMITED
To: AVECTAS LIMITED
Reel/Frame 059480/0892 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2021
From: MAGUIRE, MICHAEL; O'DEA, SHIRLEY
To: PROFECTOR LIFE SCIENCES LIMITED
Reel/Frame 057160/0699 →
Priority Claims (3)
GB 1419011 · Oct 24, 2014 · national
GB 1419012 · Oct 24, 2014 · national
GB 1419013 · Oct 24, 2014 · national
Continuity (3)
Continuation 16841236 · Apr 6, 2020
Continuation 15521192
Related Publication 20210071200A1 · Mar 11, 2021